Tysabri Approved By NICE, UK
The MS Society has welcomed the decision, which will benefit nearly 3,000 people with this form of MS.Simon Gillespie, chief executive of the MS Society, said: “We welcome confirmation of NICE’s decision to approve Tysabri, which represents a vital treatment option for people with highly active relapsing remitting MS.”The health trusts now have three months to make Tysabri available and we hope there are no unnecessary delays.
